Villere ST Denis J & Co. LLC Sells 3,005 Shares of Johnson & Johnson $JNJ

Villere ST Denis J & Co. LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 130,080 shares of the company’s stock after selling 3,005 shares during the quarter. Johnson & Johnson comprises about 2.3% of Villere ST Denis J & Co. LLC’s portfolio, making the stock its 21st largest holding. Villere ST Denis J & Co. LLC’s holdings in Johnson & Johnson were worth $24,119,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at $28,000. Semmax Financial Advisors Inc. grew its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. GFG Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter worth $35,000. Finally, Signature Resources Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after buying an additional 184 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Leerink Partners raised their target price on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. TD Cowen increased their price target on Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $233.73.

Johnson & Johnson Trading Up 1.0%

Shares of JNJ opened at $233.11 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $235.20. The firm has a market cap of $561.62 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 2.24 and a beta of 0.35. The business’s fifty day moving average is $211.74 and its 200-day moving average is $192.73.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Multiple analyst upgrades and higher price targets — Morgan Stanley upgraded JNJ to Overweight and raised its PT to $262, RBC lifted its PT to $255 with an Outperform rating, BofA nudged its PT to $227, and other outlets report a PT raised to $265; these moves signal stronger analyst conviction on JNJ’s earnings and margin outlook. Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 RBC Raises Price Target on Johnson & Johnson to $255 BofA lifts PT on Johnson & Johnson (JNJ) to $227 from $221 – here’s why Johnson & Johnson (NYSE:JNJ) Price Target Raised to $265.00
• Positive Sentiment: MedTech/product progress: J&J MedTech announced updates to its Varipulse product and a new ultrasound catheter, which can expand procedure use and revenue potential in vascular/interventional markets. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter
• Positive Sentiment: Commercial rollout: J&J launched the first daily-disposable multifocal toric contact lens for astigmatic presbyopic patients in the U.K. and Ireland (ACUVUE®), supporting the consumer/vision revenue stream. Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia
• Positive Sentiment: Investor access: Management will present at the TD Cowen Health Care Conference on March 3 — a chance to hear updated guidance, pipeline milestones and margin drivers directly from management. Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Context piece: A Forbes analysis reviews JNJ’s ~52% run over the past nine months, attributing gains to improved earnings, product wins and legal progress — useful background but not an immediate catalyst. What’s Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.